Literature DB >> 21690622

Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding.

Abhay Dhand1, Arnold S Bayer, Joseph Pogliano, Soo-Jin Yang, Michael Bolaris, Victor Nizet, Guiquing Wang, George Sakoulas.   

Abstract

We used daptomycin plus antistaphylococcal β-lactams (ASBL) to clear refractory MRSA bacteremia. In vitro studies showed enhanced daptomycin bactericidal activity, increased membrane daptomycin binding, and decrease in positive surface charge induced by ASBLs against daptomycin nonsusceptible MRSA. Addition of ASBLs to daptomycin may be of benefit in refractory MRSA bacteremia. (Although the official designation is "daptomycin nonsusceptiblity," we will use the term "daptomycin-resistance" in this paper for facility of presentation.).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21690622      PMCID: PMC3697476          DOI: 10.1093/cid/cir340

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

1.  A vital stain for studying membrane dynamics in bacteria: a novel mechanism controlling septation during Bacillus subtilis sporulation.

Authors:  J Pogliano; N Osborne; M D Sharp; A Abanes-De Mello; A Perez; Y L Sun; K Pogliano
Journal:  Mol Microbiol       Date:  1999-02       Impact factor: 3.501

2.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

Authors: 
Journal:  Am J Infect Control       Date:  2004-12       Impact factor: 2.918

3.  Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timed-kill curves.

Authors:  D R Snydman; L A McDermott; N V Jacobus
Journal:  J Chemother       Date:  2005-12       Impact factor: 1.714

4.  Correlation of penicillin-induced lysis of Enterococcus faecium with saturation of essential penicillin-binding proteins and release of lipoteichoic acid.

Authors:  S al-Obeid; L Gutmann; R Williamson
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

5.  Pharmacokinetics of nafcillin in patients with renal failure.

Authors:  C R Diaz; J G Kane; R H Parker; F R Pelsor
Journal:  Antimicrob Agents Chemother       Date:  1977-07       Impact factor: 5.191

6.  Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect").

Authors:  Soo-Jin Yang; Yan Q Xiong; Susan Boyle-Vavra; Robert Daum; Tiffanny Jones; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

7.  Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.

Authors:  Tiffanny Jones; Michael R Yeaman; George Sakoulas; Soo-Jin Yang; Richard A Proctor; Hans-Georg Sahl; Jacques Schrenzel; Yan Q Xiong; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

8.  Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus.

Authors:  Kenneth H Rand; Herbert J Houck
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

9.  Clinical identifiers of complicated Staphylococcus aureus bacteremia.

Authors:  Vance G Fowler; Maren K Olsen; G Ralph Corey; Christopher W Woods; Christopher H Cabell; L Barth Reller; Allen C Cheng; Tara Dudley; Eugene Z Oddone
Journal:  Arch Intern Med       Date:  2003-09-22

10.  Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis.

Authors:  Sara E Cosgrove; George Sakoulas; Eli N Perencevich; Mitchell J Schwaber; Adolf W Karchmer; Yehuda Carmeli
Journal:  Clin Infect Dis       Date:  2002-12-13       Impact factor: 9.079

View more
  94 in total

1.  High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  José M Miró; José M Entenza; Ana Del Río; Maria Velasco; Ximena Castañeda; Cristina Garcia de la Mària; Marlyse Giddey; Yolanda Armero; Juan M Pericàs; Carlos Cervera; Carlos A Mestres; Manuel Almela; Carlos Falces; Francesc Marco; Philippe Moreillon; Asuncion Moreno
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

Review 2.  Evolving resistance among Gram-positive pathogens.

Authors:  Jose M Munita; Arnold S Bayer; Cesar A Arias
Journal:  Clin Infect Dis       Date:  2015-09-15       Impact factor: 9.079

Review 3.  Mechanisms of drug resistance: daptomycin resistance.

Authors:  Truc T Tran; Jose M Munita; Cesar A Arias
Journal:  Ann N Y Acad Sci       Date:  2015-10-23       Impact factor: 5.691

4.  Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.

Authors:  Ashley D Hall Snyder; Brian J Werth; Poochit Nonejuie; John P McRoberts; Joe Pogliano; George Sakoulas; Juwon Yim; Nivedita Singh; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

5.  Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.

Authors:  Kimberly C Claeys; Evan J Zasowski; Anthony M Casapao; Abdalhamid M Lagnf; Jerod L Nagel; Cynthia T Nguyen; Jessica A Hallesy; Mathew T Compton; Keith S Kaye; Donald P Levine; Susan L Davis; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

6.  Antibiotics and Staphylococcus aureus--more than meets the MIC.

Authors:  Benjamin P Howden
Journal:  J Mol Med (Berl)       Date:  2014-02       Impact factor: 4.599

Review 7.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

8.  Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment.

Authors:  Pamela A Moise; Maria Amodio-Groton; Mohamad Rashid; Kenneth C Lamp; Holly L Hoffman-Roberts; George Sakoulas; Min J Yoon; Suzanne Schweitzer; Anjay Rastogi
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

9.  Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.

Authors:  B J Werth; C Vidaillac; K P Murray; K L Newton; G Sakoulas; P Nonejuie; J Pogliano; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2013-02-19       Impact factor: 5.191

10.  Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an In Vitro Biofilm Model.

Authors:  Seyedehameneh Jahanbakhsh; Nivedita B Singh; Juwon Yim; Razieh Kebriaei; Jordan R Smith; Katherine Lev; T T Tran; Warren E Rose; Cesar A Arias; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.